Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | SHBG | P04278 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.60 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.60 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.58 |
| ▸ | AR | P10275 | 2/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10274137 | 1.00 | MEN1 (0.74) | MEN1KMT2ASHBGPOLBMAPK1 | |
| SCHEMBL10274435 | 1.00 | MEN1 (0.74) | MEN1KMT2ASHBGPOLBMAPK1 | |
| SCHEMBL13160896 | 1.00 | MEN1 (0.74) | MEN1KMT2ASHBGPOLBMAPK1 | |
| SCHEMBL15274236 | 1.00 | MEN1 (0.74) | MEN1KMT2ASHBGPOLBMAPK1 | |
| SCHEMBL10273261 | 1.00 | MEN1 (0.74) | MEN1KMT2ASHBGPOLBMAPK1 | |
| SCHEMBL13630725 | 1.00 | MEN1 (0.74) | MEN1KMT2ASHBGPOLBMAPK1 | |
| SCHEMBL15369418 | 0.93 | MEN1 (0.64) | MEN1KMT2ASHBGPOLBMAPK1 | |
| SCHEMBL10274139 | 0.93 | MEN1 (0.64) | MEN1KMT2ASHBGPOLBMAPK1 | |
| SCHEMBL10273925 | 0.93 | MEN1 (0.64) | MEN1KMT2ASHBGPOLBMAPK1 | |
| SCHEMBL10274338 | 0.93 | MEN1 (0.64) | MEN1KMT2ASHBGPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4245369-A2 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, LLC | 2023-06-22 | — | — | US | disclosed |
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, LLC | 2023-06-22 | — | — | US | disclosed |
| EP-2753632-B1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-3865135-A2 | NEUROACTIVE STEROIDS FOR USE IN THERAPY | Sage Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210147470-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10759828-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| WO-2013036835-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120190659-A1 | ANGIOGENESIS INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190659-A1 | ANGIOGENESIS INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011088160-A2 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | MEN1 3628/4885KMT2A 2700/4885SHBG 69/4885 |
| US-20210147470-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | MEN1 560/4885KMT2A 2834/4885SHBG 101/4885 |
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CYP21A2, CYP24A1, HSD17B2 | MEN1 264/4885KMT2A 2872/4885SHBG 9/4885 |
| US-20120190659-A1 | ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | MEN1 3581/4885KMT2A 4604/4885SHBG 1035/4885 |
| US-10759828-B2 | Neuroactive steroids, compositions, and uses thereof | CHRNB4, CHRNB3, MC2R | MEN1 560/4885KMT2A 2834/4885SHBG 101/4885 |
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | MEN1 549/4885KMT2A 2822/4885SHBG 107/4885 |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | MEN1 549/4885KMT2A 2822/4885SHBG 107/4885 |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | CYP4A11, HSD17B11, CYP21A2 | MEN1 2870/4885KMT2A 2814/4885SHBG 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.